Dizziness

St. Joseph's Children's Hospital First in Tampa Bay to Implant Leadless Pacemaker in Pediatric Heart Patient

Retrieved on: 
Friday, February 2, 2024

TAMPA, Fla., Feb. 2, 2024 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital recently implanted its first leadless pacemaker, the first among all Tampa Bay hospitals to leverage this advanced technology in a pediatric patient.

Key Points: 
  • TAMPA, Fla., Feb. 2, 2024 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital recently implanted its first leadless pacemaker, the first among all Tampa Bay hospitals to leverage this advanced technology in a pediatric patient.
  • The procedure was performed by Dr. Kelvin Lau, director of pediatric electrophysiology at St. Joseph's Children's Hospital, on a teenage girl who was born with isolated congenital heart block.
  • The Patel Children's Heart Institute at St. Joseph's Children's Hospital is home to the Tampa Bay area's only comprehensive congenital heart disease program.
  • A partnership between St. Joseph's Children's Hospital and UPMC Children's Hospital of Pittsburgh provides families across Florida with unprecedented access to the highest level of pediatric heart care available.

MemorialCare Launches New Women's Heart Center and Recruits Nissi Suppogu, M.D. as Medical Director - Creating Sub-Specialized Women's Heart Health Center in Community

Retrieved on: 
Thursday, February 1, 2024

FOUNTAIN VALLEY, Calif., Feb. 1, 2024 /PRNewswire/ -- MemorialCare, a prominent nonprofit Southern California integrated health system, has announced the launch of the Women's Heart Center at the MemorialCare Heart & Vascular Institute – a specialized center dedicated solely to expertise in education, prevention, early diagnosis, and timely management of women-specific cardiac presentations across their lifespan. The Women's Heart Center's first site will be in conjunction with Long Beach Medical Center and MemorialCare Medical Group, with future plans to expand to additional MemorialCare sites in Orange County.

Key Points: 
  • The Women's Heart Center's first site will be in conjunction with Long Beach Medical Center and MemorialCare Medical Group , with future plans to expand to additional MemorialCare sites in Orange County.
  • To lead a dynamic and distinctive program such as this, MemorialCare has recruited and appointed Nissi Suppogu, M.D.
  • as the medical director of the Women's Heart Center.
  • Dr. Suppogu is fellowship trained, meaning she has two years of additional sub-specialty training and education in women's heart health.

Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Retrieved on: 
Monday, January 29, 2024

“Together with the recent HYQVIA approval in the U.S., we can now offer induction and maintenance therapy options to adults living with CIDP that may accommodate their personal treatment needs.”

Key Points: 
  • “Together with the recent HYQVIA approval in the U.S., we can now offer induction and maintenance therapy options to adults living with CIDP that may accommodate their personal treatment needs.”
    The approval is based on results from a prospective, open-label, single-arm, multicenter clinical study (ADVANCE-CIDP 2) that evaluated the efficacy and safety of GAMMAGARD LIQUID in adults with CIDP who developed a relapse in the randomized, double-blinded, placebo-controlled study evaluating efficacy, safety and tolerability of HYQVIA (ADVANCE-CIDP 1) in adults with CIDP.
  • Efficacy in ADVANCE-CIDP 2 was based on responder rate, where a responder was defined as a subject who demonstrated an improvement of functional disability.
  • The responder rate was 94.4% (N=18, 95% CI: 74.2% to 99.0%).
  • “Because CIDP is a progressive and complex disease, multiple treatment options are needed, and clinicians now have an additional therapy that can help adults with CIDP manage their disease.”
    GAMMAGARD LIQUID is the only IVIG with multiple neuromuscular disorder indications in the U.S. since it is now approved for CIDP and it is the only FDA-approved IVIG to treat multifocal motor neuropathy as a maintenance therapy to improve muscle strength and disability in adults.1 It is also indicated in the U.S. as a replacement therapy for people two years of age or older living with primary immunodeficiency.1

As Winter Storms Continue, CPSC Urges Families to Take Steps to Prevent Carbon Monoxide Poisoning and Fires

Retrieved on: 
Friday, January 19, 2024

WASHINGTON, Jan. 19, 2024 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) is urging consumers to take steps to protect themselves from carbon monoxide (CO) poisoning and fires as winter storms and bitter cold continue to impact millions of Americans.

Key Points: 
  • WASHINGTON, Jan. 19, 2024 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) is urging consumers to take steps to protect themselves from carbon monoxide (CO) poisoning and fires as winter storms and bitter cold continue to impact millions of Americans.
  • CO poisoning from portable generators can happen so quickly that exposed persons may become unconscious before recognizing the symptoms of nausea, dizziness or weakness.
  • Opening doors or windows will not provide enough ventilation to prevent the buildup of lethal levels of CO.
  • It may be convenient, but it's too close to home and puts your family at risk of CO poisoning.

As Winter Storms Impact Millions CPSC Issues Safety Tips to Help Families Prevent Carbon Monoxide Poisoning and Fires

Retrieved on: 
Wednesday, January 10, 2024

WASHINGTON, Jan. 10, 2024 /PRNewswire/ -- As winter storms impact much of the country this week, the U.S. Consumer Product Safety Commission (CPSC) is urging consumers to take steps to protect themselves from carbon monoxide (CO) poisoning and fires.

Key Points: 
  • WASHINGTON, Jan. 10, 2024 /PRNewswire/ -- As winter storms impact much of the country this week, the U.S. Consumer Product Safety Commission (CPSC) is urging consumers to take steps to protect themselves from carbon monoxide (CO) poisoning and fires.
  • CO poisoning from portable generators can happen so quickly that exposed persons may become unconscious before recognizing the symptoms of nausea, dizziness or weakness.
  • In the case of a power outage, follow these important life-saving tips:
    NEVER operate a portable generator inside a home, garage, basement, crawlspace or shed.
  • Opening doors or windows will not provide enough ventilation to prevent the buildup of lethal levels of CO.

Mindpath Health releases Holiday Hangover: Why Dry January May Be Right for You

Retrieved on: 
Wednesday, January 10, 2024

You've probably heard of Dry January if you've been on social media in the last ten years.

Key Points: 
  • You've probably heard of Dry January if you've been on social media in the last ten years.
  • Though plenty of apps help track your progress, Dry January is as low-tech as you want it to be.
  • This article was written by Andrew Monasterio, PMHNP-BC, DNP, a board-certified psychiatric nurse practitioner with Mindpath College Health in Isla Vista, California.
  • Mindpath Health is a leading provider of high-quality outpatient behavioral health services, offering in-person and telehealth visits.

OCUTRX Debuts Latest AR/XR Vision Headset at CES 2024: Revealing Expanded Uses, Surging Global Interest, and New Pre-Order Opportunities

Retrieved on: 
Tuesday, January 9, 2024

Ocutrx's OcuLenz, an innovative AR/XR headset, is engineered to address advanced macular degeneration (AMD), the leading cause of vision loss among adults over 65 .

Key Points: 
  • Ocutrx's OcuLenz, an innovative AR/XR headset, is engineered to address advanced macular degeneration (AMD), the leading cause of vision loss among adults over 65 .
  • Using advanced pixel manipulation, it overlays high-contrast images onto the user's field of view, compensating for AMD's central vision loss by shifting images to the peripheral vision.
  • Ocutrx invites attendees of the CES ShowStoppers event tonight to visit their booth for an exclusive live demonstration of the OcuLenz headset.
  • Additionally, to access our comprehensive press kit, which includes further insights and visuals on the OcuLenz headset, see our dedicated press kit .

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised